With the Orphan Drug indications, we believe MANF
Post# of 30027
Posted On: 09/15/2015 10:10:48 PM
Quote:
With the Orphan Drug indications, we believe MANF is highly attractive to potential partners. The candidate could help AMBS negotiate a favorable terms with potential partners for non-dilutive funding for Phase I and Phase II clinical trials.
Quote:
We believe the up-list will act as a major catalyst to drive institutional awareness in the story, and that several pending catalysts over the next 15 months, including the AMDX sales / spin-off, starting human clinical trials with MANF , reporting results from the eltoprazine Phase IIb data, and the ESS Phase IIa data should allow for the realization of a significantly higher stock price.
http://scr.zacks.com/News/Press-Releases/Pres...fault.aspx
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼